Product Description
Mechanisms of Action: IMPDH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vertex
Company Location: Eastern America
Company CEO: Reshma Kewalramani
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: COVID-19|Hepatitis A|Hepatitis C, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04410354 |
VC-02-01 | P2 |
Terminated |
COVID-19 |
2020-12-01 |
64% |
2020-12-12 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
NCT00088504 |
VX03-497-205 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/02/2023 |
News Article |
High Potency Active Pharmaceutical Ingredients Market to Reach a Revenue of Around US$ 23.3 Billion by the End of 2023 at a CAGR of 11.1%, States Persistence Market Research |
|
12/21/2021 |
PubMed |
A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors. |
|
12/17/2021 |
PubMed |
An update of anti-viral treatment of COVID-19. |
|
07/22/2021 |
PubMed |
In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19. |
|
10/28/2020 |
News Article |
BioSig Issues October 2020 Shareholder Update Letter |
|
10/26/2020 |
News Article |
ViralClear halts its Phase 2 Hospitalized COVID-19 Trial |
|
10/07/2020 |
News Article |
Sales Grow as Public Opinion on PPE Shifts |